Expression of Metalloprotease Insulin-degrading Enzyme Insulysin in Normal and Malignant Human Tissues

Overview

Journal Int J Mol Med

Specialty Genetics

Date 2008 Sep 25

PMID 18813847

Citations 14

Authors

Christina Yfanti

Karin Mengele

Apostolos Gkazepis

Gregor Weirich

Cecylia Giersig

Wen-Liang Kuo

Wei-Jen Tang

Marsha Rosner

Manfred Schmitt

Affiliations

Soon will be listed here.

Abstract

Insulin-degrading enzyme (IDE, insulysin, insulinase; EC 3.4.22.11), a thiol metalloendopeptidase, is involved in intracellular degradation of insulin, thereby inhibiting its translocation and accumulation to the nucleus. Recently, protein expression of IDE has been demonstrated in the epithelial ducts of normal breast and breast cancer tissue. Utilizing four different antibodies generated against different epitopes of the IDE molecule, we performed Western blot analysis and immunohistochemical staining on several normal human tissues, on a plethora of tumor cell lines of different tissue origin, and on malignant breast and ovarian tissue. Applying the four IDE-directed antibodies, we demonstrated IDE expression at the protein level, by means of immunoblotting and immunocytochemistry, in each of the tumor cell lines analyzed. Insulin-degrading enzyme protein expression was found in normal tissues of the kidney, liver, lung, brain, breast and skeletal muscle, as well as in breast and ovarian cancer tissues. Immunohistochemical visualization of IDE indicated cytoplasmic localization of IDE in each of the cell lines and tissues assessed. In conclusion, we performed for the first time a wide-ranging survey on IDE protein expression in normal and malignant tissues and cells thus extending our knowledge on the cellular and tissue distribution of IDE, an enzyme which to date has mainly been studied in connection with Alzheimer's disease and diabetes but not in cancer.

Citing Articles

Prognostic Role of M6A-Associated Immune Genes and Cluster-Related Tumor Microenvironment Analysis: A Multi-Omics Practice in Stomach Adenocarcinoma.

Luo N, Fu M, Zhang Y, Li X, Zhu W, Yang F Front Cell Dev Biol. 2022; 10:935135.

PMID: 35859893 PMC: 9291731. DOI: 10.3389/fcell.2022.935135.

Insulin-Degrading Enzyme, an Under-Estimated Potential Target to Treat Cancer?.

Lesire L, Leroux F, Deprez-Poulain R, Deprez B Cells. 2022; 11(7).

PMID: 35406791 PMC: 8998118. DOI: 10.3390/cells11071228.

Insulin-Degrading Enzyme Regulates the Proliferation and Apoptosis of Porcine Skeletal Muscle Stem Cells Myostatin/MYOD Pathway.

Wang B, Guo J, Zhang M, Liu Z, Zhou R, Guo F Front Cell Dev Biol. 2021; 9:685593.

PMID: 34712657 PMC: 8545900. DOI: 10.3389/fcell.2021.685593.

Identification of a Prognostic Signature Based on the Expression of Genes Related to the Insulin Pathway in Early Breast Cancer.

Gennari A, Sormani M, Puntoni M, Martini V, Amaro A, Bruzzi P Breast Care (Basel). 2021; 16(3):299-306.

PMID: 34248472 PMC: 8251663. DOI: 10.1159/000509207.

Ablation of amyloid precursor protein increases insulin-degrading enzyme levels and activity in brain and peripheral tissues.

Kulas J, Franklin W, Smith N, Manocha G, Puig K, Nagamoto-Combs K Am J Physiol Endocrinol Metab. 2018; 316(1):E106-E120.

PMID: 30422705 PMC: 6417684. DOI: 10.1152/ajpendo.00279.2018.

References

Bennett R, Duckworth W, Hamel F . Degradation of amylin by insulin-degrading enzyme. J Biol Chem. 2000; 275(47):36621-5. DOI: 10.1074/jbc.M006170200. View

Chang L, Stout L, Wong W, Buls J, Rothenberger D, Shier W . Immunohistochemical localization of insulin-degrading enzyme along the rat intestine, in the human colon adenocarcinoma cell line (Caco-2), and in human ileum. J Pharm Sci. 1997; 86(1):116-9. DOI: 10.1021/js960035q. View

Chesneau V, Rosner M . Functional human insulin-degrading enzyme can be expressed in bacteria. Protein Expr Purif. 2000; 19(1):91-8. DOI: 10.1006/prep.2000.1217. View

Udrisar D, Wanderley M, Porto R, Cardoso C, Barbosa M, Camberos M . Androgen- and estrogen-dependent regulation of insulin-degrading enzyme in subcellular fractions of rat prostate and uterus. Exp Biol Med (Maywood). 2005; 230(7):479-86. DOI: 10.1177/153537020523000706. View

Hamel F, Mahoney M, Duckworth W . Degradation of intraendosomal insulin by insulin-degrading enzyme without acidification. Diabetes. 1991; 40(4):436-43. DOI: 10.2337/diab.40.4.436. View

Kwak S, Cho Y, Moon M, Kim J, Park B, Cheong H . Association of polymorphisms in the insulin-degrading enzyme gene with type 2 diabetes in the Korean population. Diabetes Res Clin Pract. 2007; 79(2):284-90. DOI: 10.1016/j.diabres.2007.08.017. View

Nikoshkov A, Kamel A, Fernstrom M, Zierath J, Norgren S, Luthman H . Insulin-degrading enzyme identified as a candidate diabetes susceptibility gene in GK rats. Hum Mol Genet. 2000; 9(14):2149-58. DOI: 10.1093/hmg/9.14.2149. View

Goldfine I, Williams J, Bailey A, Wong K, Iwamoto Y, Yokono K . Degradation of insulin by isolated mouse pancreatic acini. Evidence for cell surface protease activity. Diabetes. 1984; 33(1):64-72. DOI: 10.2337/diab.33.1.64. View

Duckworth W . Insulin degradation: mechanisms, products, and significance. Endocr Rev. 1988; 9(3):319-45. DOI: 10.1210/edrv-9-3-319. View

10.

Farris W, Mansourian S, Chang Y, Lindsley L, Eckman E, Frosch M . Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A. 2003; 100(7):4162-7. PMC: 153065. DOI: 10.1073/pnas.0230450100. View

11.

Duckworth W, Hamel F . Cellular and endosomal insulin degradation. Adv Second Messenger Phosphoprotein Res. 1990; 24:521-8. View

12.

Valera Mora M, Scarfone A, Calvani M, Greco A, Mingrone G . Insulin clearance in obesity. J Am Coll Nutr. 2003; 22(6):487-93. DOI: 10.1080/07315724.2003.10719326. View

13.

Yokono K, Imamura Y, Sakai H, Baba S . Insulin-degrading activity of plasma membranes from rat skeletal muscle: its isolation, characterization, and biologic significance. Diabetes. 1979; 28(9):810-7. DOI: 10.2337/diab.28.9.810. View

14.

Radulescu R, Doklea E, Kehe K, Muckter H . Nuclear colocalization and complex formation of insulin with retinoblastoma protein in HepG2 human hepatoma cells. J Endocrinol. 2000; 166(2):R1-4. DOI: 10.1677/joe.0.166r001. View

15.

Rawlings N, Morton F, Kok C, Kong J, Barrett A . MEROPS: the peptidase database. Nucleic Acids Res. 2007; 36(Database issue):D320-5. PMC: 2238837. DOI: 10.1093/nar/gkm954. View

16.

Duckworth W . Insulin and glucagon binding and degradation by kidney cell membranes. Endocrinology. 1978; 102(6):1766-74. DOI: 10.1210/endo-102-6-1766. View

17.

EXTON J . Some thoughts on the mechanism of action of insulin. Diabetes. 1991; 40(5):521-6. DOI: 10.2337/diab.40.5.521. View

18.

Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S . Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science. 2000; 290(5500):2302-3. DOI: 10.1126/science.290.5500.2302. View

19.

Kurochkin I . Amyloidogenic determinant as a substrate recognition motif of insulin-degrading enzyme. FEBS Lett. 1998; 427(2):153-6. DOI: 10.1016/s0014-5793(98)00422-0. View

20.

Lynch J, George A, Eisenhauer P, Conn K, Gao W, Carreras I . Insulin degrading enzyme is localized predominantly at the cell surface of polarized and unpolarized human cerebrovascular endothelial cell cultures. J Neurosci Res. 2006; 83(7):1262-70. DOI: 10.1002/jnr.20809. View